Impact News +++ XETR: DE000A2E4SV8: Wiederaufnahme/Resumption (XETRA) +++ CYAN Aktie +17,44%

NEKTAR THERAPEUTICS Aktie

>Aktienkurs

54.98 EUR +3.2% (TradegateBSX)

Ask: 54.98 EUR / 93 Stück

Bid: 53.8 EUR / 96 Stück

Tagesumsatz: 41 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: +2,0%

1 Monat: -9,5%

3 Monate: -20,7%

6 Monate: +38,1%

1 Jahr: 0%

laufendes Jahr: +42,6%

>NEKTAR THERAPEUTICS Aktie

Name:

NEKTAR THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6402683063 / A419UB

Symbol/ Ticker:

ITH0 (Frankfurt) / NKTR (NASDAQ)

Kürzel:

FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR

Index:

Webseite:

https://www.nektar.com/

Profil:

Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States an..
>Volltext..

Marktkapitalisierung:

1795.92 Mio. EUR

Unternehmenswert:

1426.56 Mio. EUR

Umsatz:

48.54 Mio. EUR

EBITDA:

-108.12 Mio. EUR

Nettogewinn:

-137.95 Mio. EUR

Gewinn je Aktie:

-7.35 EUR

Schulden:

125.15 Mio. EUR

Liquide Mittel:

115.06 Mio. EUR

Operativer Cashflow:

-177.79 Mio. EUR

Bargeldquote:

9.85

Umsatzwachstum:

-40.29%

Gewinnwachstum:

-11.27%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 1.391.753 Euro.

Suchwörter:

NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC

Letzte Datenerhebung:

19.06.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 33.79 Mio. St.

Frei handelbar: 96.53%

Leerverk. Aktien: 13.65%

Rückkaufquote: -34.5%

Mitarbeiter: 63

Umsatz/Mitarb.: 0.76 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 151.05%

Bewertung:

KGV: -

KGV lG: -

KUV: 26.07

KBV: 2.15

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 98.65%

Gewinnmarge: -284.18%

Operative Marge: -224.08%

Managementeffizenz:

Gesamtkaprendite: -31.01%

Eigenkaprendite: -53.6%

>Peer Group

Gesundheit, Hauterkrankungen & -behandlung/ Dermatologie, Stoffwechselerkrankungen (Diabetes/ Adipositas), Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>Chart & Kurs - NASDAQ

>Alle News

19.06.26 - 03:01	Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 603176 USD (Insiderkauf)
	Robin, Howard W. - Vorstand - Tag der Transaktion: 2026-06-16...

19.06.26 - 03:01	Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 611880 USD (Insiderkauf)
	Robin, Howard W. - Vorstand - Tag der Transaktion: 2026-06-17...

18.06.26 - 03:01	Insiderhandel: Chief R&D Officer verkauft Aktien von Nektar Therapeutics im Wert von 336212 USD (Insiderkauf)
	Zalevsky, Jonathan - Vorstand - Tag der Transaktion: 2026-06-15...

03.06.26 - 22:18	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
	SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common......

28.05.26 - 00:18	Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York (PR Newswire)
	SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference......

23.05.26 - 23:00	What to Know About This Fund′s $10 Million Nektar Bet Ahead of a Key Phase 3 Launch (Fool)
	Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations....

22.05.26 - 05:01	Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 29086 USD (Insiderkauf)
	Robin, Howard W. - Vorstand - Tag der Transaktion: 2026-05-19...

22.05.26 - 05:01	Insiderhandel: Chief R&D Officer verkauft Aktien von Nektar Therapeutics im Wert von 13036 USD (Insiderkauf)
	Zalevsky, Jonathan - Vorstand - Tag der Transaktion: 2026-05-19...

07.05.26 - 22:18	Nektar Therapeutics Reports First Quarter 2026 Financial Results (PR Newswire)
	SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31,......

07.05.26 - 16:03	Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR (PR Newswire)
	NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of......

05.05.26 - 18:00

Nektar Therapeutics: Auch nach NBC-Tenbagger noch super günstig? (Sharedeals)

Die Aktie von Nektar Therapeutics war für Mitglieder des No Brainer Club längst ein gigantischer Volltreffer mit mehr als +1.000% Performance seit Empfehlung, doch mit den neuesten Studiendaten erscheint das Chance-Risiko-Profil weiterhin günstig. Mit Blick auf zwei potenziell große Indikationen rückt das Unternehmen zunehmend in den Kreis relevanter Biotech-Wachstumswerte. Neue Studiendaten stärken die Investmentthese Am […] The post Nektar Therapeutics: Auch nach NBC-Tenbagger noch super günstig? first appeared on sharedeals.de....

05.05.26 - 16:01	NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to......

05.05.26 - 03:57	NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, May 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026......

04.05.26 - 10:03	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
	LOS ANGELES, May 4, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by......

04.05.26 - 10:03	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, May 4, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange......

01.05.26 - 22:42	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
	SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common......

01.05.26 - 18:03	Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, May 1, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU SUFFERED A LOSS ON YOUR NEKTAR......

01.05.26 - 02:42	Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR (PR Newswire)
	NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of......

30.04.26 - 15:46	NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to......

29.04.26 - 00:03	Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets (PR Newswire)
	SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Veni, vidi, vici - Ich kam, ich sah, ich siegte. (Caesar über die Schlacht bei Zela gegen Pharnakos II., 47 v. Chr.). - Gajus Julius Caesar

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram